Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04761107 · ClinicalTrials.gov registry record
Impact of COVID-19 on GU Disease
A clinical trial of COVID-19 Infection and Genitourinary Cancer, sponsored by Icahn School of Medicine at Mount Sinai.
- Active
- Registry status
- 15,240
- Enrollment target
- 1
- Study location
NCT04761107: Active study of COVID-19 Infection and Genitourinary Cancer, sponsored by Icahn School of Medicine at Mount Sinai.
NCT04761107 is a study of COVID-19 Infection and Genitourinary Cancer that is active but no longer recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 15,240 participants, above the 2,426-participant average among 21 other COVID-19 Infection trials with a reported enrollment target (528% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04761107, a study of COVID-19 Infection and Genitourinary Cancer, is active but no longer recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- ACTIVE NOT RECRUITING
- Registry status
- 15,240 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. * Disclose if the patient has or had Genitourinary cancer or benign urologic condition * Provide urine specimen for research * Provide 4 tablespoons of blood for testing blood for research. * Provide permission to access medical records, such as patient lab results, medical history, imaging reports, etc.
Primary Outcome
Proportion of patients with a new diagnosis of GU cancer and with active or past infection with SARS-Co-V-2
Conditions Studied
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,240 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2026-02 |
What the registry record for NCT04761107 still lists
NCT04761107 is an observational study that tracks outcomes without assigning an intervention. Its 15,240 participants enrollment target places it among the larger protocols in the corpus, above the 2,426-participant average among 21 other COVID-19 Infection trials with a reported enrollment target (528% higher).
The record links to 3 conditions, with COVID-19 Infection appearing as the primary indexed condition, and to 0 interventions.
NCT04761107 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04761107 about?
NCT04761107 is a clinical study titled "Impact of COVID-19 on GU Disease". The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. * Disclose if the patient has or had Genitourinary cancer or benign urologic condition * Provide urine spec...
What is the current status of trial NCT04761107?
This trial is currently active not recruiting. The enrollment target is 15,240 participants. The study started on 2021-02-18. Estimated completion is 2026-02.
What conditions does trial NCT04761107 study?
This clinical trial studies the following conditions: COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions.
Who is sponsoring clinical trial NCT04761107?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04761107 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04761107's enrollment target sits among peer trials
15,240 2nd of 21 the highest of 21 other COVID-19 Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
RECRUITING
-
Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health
RECRUITING
-
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
-
The Impact of COVID-19 on Pulmonary Procedures
RECRUITING
-
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
RECRUITING
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07000357 · 15,100 participants · Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- NCT01550575 · 15,000 participants
Patient Retrospective Outcomes (PRO)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI